Global BCG Vaccination Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG Vaccination Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
BCG Vaccination report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global BCG Vaccination market is projected to reach US$ 93 million in 2029, increasing from US$ 76 million in 2022, with the CAGR of 3.0% during the period of 2024 to 2029. Demand from Self-Procurement and UNICEF are the major drivers for the industry.
The tuberculosis (TB) vaccination market is driven by the global efforts to combat TB and the increasing burden of the disease in high-risk populations. TB is a highly contagious bacterial infection that poses a significant public health challenge worldwide. Vaccination against TB, primarily through the Bacille Calmette-Guérin (BCG) vaccine, is essential in reducing TB incidence and severity, especially in endemic regions. The rise in TB cases and drug-resistant strains contribute to market growth as governments and healthcare organizations focus on prevention strategies. Moreover, advancements in vaccine research and development, including novel TB vaccines under investigation, have the potential to further improve TB control efforts. However, the market also faces challenges, including the variable efficacy of the BCG vaccine against different forms of TB and the need for improved vaccine coverage in high-burden areas. Additionally, addressing vaccine supply and distribution challenges and ensuring equitable access to TB vaccination can pose obstacles for comprehensive disease control. To succeed, companies must focus on research and development to offer innovative TB vaccine candidates, collaborate with global health initiatives to promote vaccination campaigns, and address the challenges to meet the increasing demand for effective TB prevention solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccination market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC – Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Self-Procurement
UNICEF
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the BCG Vaccination market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of BCG Vaccination, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the BCG Vaccination industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of BCG Vaccination in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, BCG Vaccination introduction, etc. BCG Vaccination Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of BCG Vaccination market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
BCG Vaccination report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global BCG Vaccination market is projected to reach US$ 93 million in 2029, increasing from US$ 76 million in 2022, with the CAGR of 3.0% during the period of 2024 to 2029. Demand from Self-Procurement and UNICEF are the major drivers for the industry.
The tuberculosis (TB) vaccination market is driven by the global efforts to combat TB and the increasing burden of the disease in high-risk populations. TB is a highly contagious bacterial infection that poses a significant public health challenge worldwide. Vaccination against TB, primarily through the Bacille Calmette-Guérin (BCG) vaccine, is essential in reducing TB incidence and severity, especially in endemic regions. The rise in TB cases and drug-resistant strains contribute to market growth as governments and healthcare organizations focus on prevention strategies. Moreover, advancements in vaccine research and development, including novel TB vaccines under investigation, have the potential to further improve TB control efforts. However, the market also faces challenges, including the variable efficacy of the BCG vaccine against different forms of TB and the need for improved vaccine coverage in high-burden areas. Additionally, addressing vaccine supply and distribution challenges and ensuring equitable access to TB vaccination can pose obstacles for comprehensive disease control. To succeed, companies must focus on research and development to offer innovative TB vaccine candidates, collaborate with global health initiatives to promote vaccination campaigns, and address the challenges to meet the increasing demand for effective TB prevention solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccination market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC – Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Segment by Application
Self-Procurement
UNICEF
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the BCG Vaccination market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of BCG Vaccination, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the BCG Vaccination industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of BCG Vaccination in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, BCG Vaccination introduction, etc. BCG Vaccination Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of BCG Vaccination market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices